Ghent University Academic Bibliography

Your filters: cql: author="Lambrechts, Diether" or (type any "bookEditor issueEditor" and editor="Lambrechts, Diether")

Add to list
- Journal Article
- A1
- open access
Pan-cancer single-cell atlases of mouse and human tumor-associated dendritic cells

Aarushi A. Caro, Daliya Kancheva, Eva Hadadi, Bram Boeckx, Clint De Nolf (UGent) , Pauline M. R. Bardet, Kevin Verstaen (UGent) , Luqing Li, Lobna Oueslati, Nil Figueras-Duch, et al.

(2026) NATURE COMMUNICATIONS. 17(1).
Add to list
- Journal Article
- A1
- open access
Cytotoxic NK cells impede response to checkpoint immunotherapy in melanoma with an immune-excluded phenotype

Joanna Pozniak, Niccolò Roda, Ewout Landeloos, Asier Antoranz, Yannick Van Herck, Amber De Visscher, Philip Georg Demaerel, Lukas Vanwynsberghe, Jeroen Declercq, Christos Gkemisis, et al.

(2025) CANCER DISCOVERY. 15(9). p.1819-1834
Add to list
- Miscellaneous
- open access
Beyond BRCA deficiency : clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma

Dale Garsed, Tibor Zwimpfer, Sian Fereday, Ahwan Pandey, Dinuka Ariyaratne, Madawa Jayawardana, Laura Twomey, Céline Laumont, Catherine Kennedy, Adelyn Bolithon, et al.

(2025) Research Square.
Add to list
- Journal Article
- A1
- open access
A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer : ALEPRO trial

Tine Ottenbourgs, Toon van Gorp, Frédéric Kridelka, Thaïs Baert, Hannelore Denys (UGent) , Frédéric Selle, Inge Baas (UGent) , Anne-Sophie Van Rompuy, Diether Lambrechts and Els Van Nieuwenhuysen

(2024) INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 34(4). p.627-630
Add to list
- Journal Article
- A1
- open access
Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial

Emiel De Jaeghere (UGent) , Hannelore Hamerlinck (UGent) , Sandra Tuyaerts, Lien Lippens (UGent) , An M.T. Van Nuffel, Regina Baiden-Amissah, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, et al.

(2024) GYNECOLOGIC ONCOLOGY. 191. p.275-286
Add to list
- Miscellaneous
- open access
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022)

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, An M. T. Van Nufel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens (UGent) , Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, et al.

(2024) CANCER IMMUNOLOGY IMMUNOTHERAPY. 74(1).
Add to list
CD4+T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy

Amelie Franken, Michel Bila, Aurelie Mechels, Sam Kint (UGent) , Jeroen Van Dessel, Valentina Pomella, Sebastiaan Vanuytven, Gino Philips, Orian Bricard, Jieyi Xiong, et al.

(2024) IMMUNITY. 57(3). p.541-558.e7
Add to list
- Journal Article
- A1
- open access
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer : a phase 2 adaptive trial

Iris Nederlof, Olga I. Isaeva, Manon de Graaf, Robbert C. A. M. Gielen, Noor A. M. Bakker, Adrianne L. Rolfes, Hannah Garner, Bram Boeckx, Joleen J. H. Traets, Ingrid A. M. Mandjes, et al.

(2024) NATURE MEDICINE. 30(11). p.3223-3235
Add to list
- Miscellaneous
- open access
MultiNicheNet : a flexible framework for differential cell-cell communication analysis from multi-sample multi-condition single-cell transcriptomics data

Robin Browaeys (UGent) , Jeroen Gilis, Chananchida Sang-aram (UGent) , Pieter De Bleser (UGent) , Levi Hoste (UGent) , Simon Tavernier (UGent) , Diether Lambrechts, Ruth Seurinck (UGent) and Yvan Saeys (UGent)

(2023) bioRxiv.
Add to list
- Journal Article
- A1
- open access
Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study

Emiel De Jaeghere (UGent) , Sandra Tuyaerts, An M. T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Lien Lippens (UGent) , Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, et al.

(2023) CANCER IMMUNOLOGY IMMUNOTHERAPY. 72(2). p.475-491

Academic Bibliography

Pan-cancer single-cell atlases of mouse and human tumor-associated dendritic cells

Cytotoxic NK cells impede response to checkpoint immunotherapy in melanoma with an immune-excluded phenotype

Beyond BRCA deficiency : clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma

A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer : ALEPRO trial

Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study (vol 72, pg 475, 2022)

CD4+T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer : a phase 2 adaptive trial

MultiNicheNet : a flexible framework for differential cell-cell communication analysis from multi-sample multi-condition single-cell transcriptomics data

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study

Contents

Support

Contact